Navigation Links
NuvOx Pharma Begins Clinical Trial to Treat Brain Cancer
Date:8/7/2014

Tucson, AZ (PRWEB) August 07, 2014

NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, focused on developing a nanotechnology platform for reversing conditions with decreased oxygen announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer.

Glioblastoma multiforme (GBM), according to the Central Brain Tumor Registry, affects about 10,300 patients per year in the US. Average survival is only about 12-months following standard therapy, which involves surgery followed by radiation and chemotherapy. GBM, like many other forms of cancer, is known to have low oxygen (hypoxia). Hypoxia adversely affects the response of tumors to radiation therapy and NVX-108 has been shown to raise tumor oxygen levels and improve the response to radiation therapy. The clinical trial is being performed at Monash University in Melbourne Australia. GBM patients who have residual tumor after surgery are receiving an IV dose of NVX-108 during each of the 30 fractions of radiation over a 6-week period. Up to about 25 patients will be treated in the trial. The primary end-point of the trial is safety, but the study will also determine the recommended dose for the drug and provide data on the 6-month survival of the patients. After completion of the trial NuvOx plans to file an investigational new drug application with the FDA and perform a Phase IIb trial in the US.

“We are very excited about moving NVX-108 into the first therapeutic trial. The parent compound, dodecafluoropentane, was previously studied as a contrast agent and was shown to be safe. Due to market considerations it was never launched as a contrast agent. We own that regulatory data and the FDA has agreed that we can reference it in support of clinical development to treat cancer,” said Evan Unger, MD, President and CEO of NuvOx.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12071710.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System
2. Sanuvox Releases the Aseptix Dual UV Sterilization System to Help Reduce Nosocomial (HAI) Infections in Hospital Environments
3. URAC Seeks Public Comments on Revised Specialty Pharmacy and Mail Service Pharmacy Accreditation Standards and Measures
4. Good Neighbor Pharmacy’s 2014 ThoughtSpot Inspires Independent Pharmacists to Transform Their Businesses
5. Harry Race Pharmacy Named 2014 Good Neighbor Pharmacy of the Year
6. Community pharmacist intervention boosts drug adherence, reduces health-care costs
7. Pharmaceuticals Wholesaling in Australia Industry Market Research Report Now Updated by IBISWorld
8. West Coast University Launches New Doctorate of Pharmacy Program
9. PharmaVOICE Honors Five PHCG Leaders Among 100 Healthcare Visionaries
10. US Pharmaceutical Packaging Products Worth $22.1 Billion by 2018 Says a New Research Report at LifeScienceIndustryResearch.com
11. Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Rijuven Corp ... and overall health, day and night. No other wearable health technology on the market ... We wanted to give poeple more meaningful insights about their health than the usual ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... to build intelligent, connected applications, was named the best Sales Team of 2016 ... winner announcement was made today by the Software & Information Industry Association (SIIA), ...
(Date:11/30/2016)... PITTSBURGH, PA (PRWEB) , ... November 30, 2016 , ... ... my hand and arm while brushing my teeth," said an inventor from Bridgewater, N.J. ... led me to develop this handy device." , He developed the patent-pending DEFLECTOR to ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... , , Drug delivery ... value of drug delivery technologies and the anticancer drugs are difficult ... organs involved and the types of cancer as well as according ...
Breaking Medicine Technology: